Published in J Am Soc Nephrol on January 01, 2002
Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol (2009) 1.58
Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol (2006) 1.40
Relationship between lean body mass and serum renal biomarkers in healthy dogs. J Vet Intern Med (2015) 1.26
Asymmetric dimethylarginine, endothelial nitric oxide bioavailability and mortality in sepsis. PLoS One (2011) 1.15
Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in cats with chronic kidney disease. J Vet Intern Med (2014) 1.13
Clinical Interaction between Brain and Kidney in Small Vessel Disease. Cardiol Res Pract (2011) 1.10
ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol (2008) 1.08
The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis (2010) 1.05
Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int J Mol Sci (2012) 0.99
Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes. Kidney Int (2013) 0.98
Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review. Am J Nephrol (2007) 0.95
Coronary artery calcification, ADMA, and insulin resistance in CKD patients. Clin J Am Soc Nephrol (2008) 0.93
Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. J Am Soc Nephrol (2012) 0.91
Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA. Toxins (Basel) (2016) 0.90
Endothelial dysfunction and oxidative stress in polycystic kidney disease. Am J Physiol Renal Physiol (2014) 0.87
[Atherosclerosis and uremia: signifance of non-traditional risk factors]. Wien Klin Wochenschr (2003) 0.86
L-arginine and asymmetric dimethylarginine are early predictors for survival in septic patients with acute liver failure. Mediators Inflamm (2012) 0.86
Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp Nephrol (2007) 0.86
Renal function is associated with risk of atrial fibrillation after cardiac surgery. Can J Cardiol (2007) 0.86
Minor renal dysfunction: an emerging independent cardiovascular risk factor. Heart (2003) 0.86
Asymmetric dimethylarginine reference intervals determined with liquid chromatography-tandem mass spectrometry: results from the Framingham offspring cohort. Clin Chem (2009) 0.86
Mechanisms for increased cardiovascular disease in chronic kidney dysfunction. Curr Opin Nephrol Hypertens (2009) 0.86
Serum Concentrations of Symmetric Dimethylarginine and Creatinine in Dogs with Naturally Occurring Chronic Kidney Disease. J Vet Intern Med (2016) 0.84
Diabetic retinopathy is associated with elevated serum asymmetric and symmetric dimethylarginines. Diabetes Care (2009) 0.82
Asymmetric dimethylarginine in homocystinuria due to cystathionine beta-synthase deficiency: relevance of renal function. J Inherit Metab Dis (2006) 0.82
Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease. BMC Nephrol (2013) 0.81
Subclinical renal insufficiency range of estimated glomerular filtration rate and microalbuminuria are independently associated with increased arterial stiffness in never treated hypertensives. Korean Circ J (2013) 0.81
Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study. Clin Nephrol (2012) 0.81
The inhibitory effect of quercetin on asymmetric dimethylarginine-induced apoptosis is mediated by the endoplasmic reticulum stress pathway in glomerular endothelial cells. Int J Mol Sci (2014) 0.80
Role of kidney biomarkers of chronic kidney disease: An update. Saudi J Biol Sci (2014) 0.79
Darbepoetin alpha reduces oxidative stress and chronic inflammation in atherosclerotic lesions of apo E deficient mice in experimental renal failure. PLoS One (2014) 0.78
Dimethylarginines and inflammation markers in patients with chronic kidney disease undergoing dialysis. Clin Exp Med (2009) 0.78
Dimethylarginine metabolism during acute and chronic rejection of rat renal allografts. Nephrol Dial Transplant (2010) 0.78
Effect of ADMA levels on severity of erectile dysfunction in chronic kidney disease and other risk factors. Can Urol Assoc J (2016) 0.78
Renal function but not asymmetric dimethylarginine is independently associated with retinopathy in type 2 diabetes. Cardiol Res Pract (2011) 0.77
Proximal tubule cell hypothesis for cardiorenal syndrome in diabetes. Int J Nephrol (2010) 0.77
Apolipoprotein E polymorphism modulation of asymmetric dimethylarginine in hypertensive patients is determined by renal function. Lipids Health Dis (2016) 0.76
Elevated Levels of Asymmetric Dimethylarginine (ADMA) in the Pericardial Fluid of Cardiac Patients Correlate with Cardiac Hypertrophy. PLoS One (2015) 0.76
Reduced Kidney Function Is Associated With Cardiometabolic Risk Factors, Prevalent and Predicted Risk of Cardiovascular Disease in Chinese Adults: Results From the REACTION Study. J Am Heart Assoc (2016) 0.76
Arginine dimethylation products in pediatric patients with chronic kidney disease. Ann Med Surg (Lond) (2016) 0.76
Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis. World J Gastroenterol (2015) 0.76
Effect of lowering asymmetric dimethylarginine (ADMA) on vascular pathology in atherosclerotic ApoE-deficient mice with reduced renal mass. Int J Mol Sci (2014) 0.76
Relation of asymmetric dimethylarginine levels to macrovascular disease and inflammation markers in type 2 diabetic patients. J Diabetes Res (2014) 0.76
Nitric oxide status in patients with chronic kidney disease. Indian J Nephrol (2015) 0.76
Effect of enzyme replacement therapy on serum asymmetric dimethylarginine levels, coronary flow reserve and left ventricular hypertrophy in patients with Fabry disease. Clin Kidney J (2012) 0.75
Metabolomic Profiling of Arginine Metabolome Links Altered Methylation to Chronic Kidney Disease Accelerated Atherosclerosis. J Proteomics Bioinform (2015) 0.75
Positive Impact of Nutritional Interventions on Serum Symmetric Dimethylarginine and Creatinine Concentrations in Client-Owned Geriatric Cats. PLoS One (2016) 0.75
Asymmetric Dimethylarginine and Its Relation As a Biomarker in Nephrologic Diseases. Biomark Insights (2016) 0.75
eNOS Glu298Asp Polymorphism and Endothelial Dysfunction in Patients with and without End-stage Renal Disease. Balkan Med J (2016) 0.75
Positive Impact of Nutritional Interventions on Serum Symmetric Dimethylarginine and Creatinine Concentrations in Client-Owned Geriatric Dogs. PLoS One (2016) 0.75
Serum concentrations of symmetric dimethylarginine and creatinine in cats with kidney stones. PLoS One (2017) 0.75
Defining uremic arterial functional abnormalities in patients recently started on haemodialysis: combined in vivo and ex vivo assessment. PLoS One (2014) 0.75
Retracted Effects of coenzyme Q10 and α-lipoic acid supplementation in fructose fed rats. J Clin Biochem Nutr (2011) 0.75
Losartan for the Nephropathy of Sickle Cell Anemia: A Phase-2, Multi-Center Trial. Am J Hematol (2017) 0.75
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med (2005) 12.72
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med (2011) 11.11
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Nephron number in patients with primary hypertension. N Engl J Med (2003) 6.74
Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension (2012) 6.70
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol (2007) 4.59
The renal arterial resistance index and renal allograft survival. N Engl J Med (2003) 4.36
Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol (2009) 4.31
New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation (2003) 3.79
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2011) 3.48
Heavy metal--rely on gut feelings: novel diagnostic approach to test drug compliance in patients with lanthanum intake. Nephrol Dial Transplant (2007) 2.96
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
Wegener's granulomatosis. Lancet (2006) 2.83
Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int (2005) 2.78
Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity (2013) 2.74
Pathogenesis and management of hypertension after kidney transplantation. J Hypertens (2011) 2.66
SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood (2011) 2.66
Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant (2010) 2.64
Essential hypertension. Lancet (2007) 2.63
Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol (2002) 2.50
Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation (2005) 2.49
Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension (2010) 2.38
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ (2012) 2.32
Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol (2011) 2.27
Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation (2004) 2.20
Erythropoietin regulates endothelial progenitor cells. Blood (2003) 2.18
AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation (2003) 2.15
Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol (2009) 2.13
Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range. J Am Coll Cardiol (2010) 2.13
Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation (2003) 2.12
Preparation of the dialysis patient for transplantation. Nephrol Dial Transplant (2002) 2.10
Asymmetric dimethylarginine in response to recombinant tissue-type plasminogen activator and erythropoietin in acute stroke. Stroke (2013) 2.07
Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension (2005) 2.01
Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet (2003) 2.00
Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol (2005) 2.00
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press (2009) 1.98
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol (2005) 1.96
Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin Chem (2010) 1.95
Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol (2007) 1.95
A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant (2012) 1.94
Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients. Crit Care (2008) 1.94
CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol (2012) 1.92
Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int (2012) 1.92
Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis. Nephrol Dial Transplant (2006) 1.90
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke (2006) 1.88
1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol (2003) 1.86
The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrol Dial Transplant (2009) 1.86
Loss of podocyte aPKClambda/iota causes polarity defects and nephrotic syndrome. J Am Soc Nephrol (2009) 1.86
Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet (2003) 1.84
Lung-targeted RNA interference against angiopoietin-2 ameliorates multiple organ dysfunction and death in sepsis. Crit Care Med (2014) 1.83
Nephrogenesis is induced by partial nephrectomy in the elasmobranch Leucoraja erinacea. J Am Soc Nephrol (2003) 1.83
Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol (2010) 1.82
Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol (2009) 1.82
Nutritional status in dialysis patients: a European consensus. Nephrol Dial Transplant (2002) 1.81
Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation (2004) 1.81
Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. Transplantation (2003) 1.79
FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant (2010) 1.78
ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res (2003) 1.78
Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol (2005) 1.74
Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation (2009) 1.73
CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J (2010) 1.73
The effect of donor gender on graft survival. J Am Soc Nephrol (2002) 1.72
Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int (2004) 1.72
Complement 5a receptor inhibition improves renal allograft survival. J Am Soc Nephrol (2008) 1.72
Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J (2010) 1.72
Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res (2002) 1.71
Vitamin D status and mortality in chronic kidney disease. Nephrol Dial Transplant (2011) 1.71
Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol (2002) 1.70
Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury. Crit Care (2010) 1.65
MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol (2011) 1.65
Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int (2012) 1.65
Rapid screening of glomerular slit diaphragm integrity in larval zebrafish. Am J Physiol Renal Physiol (2007) 1.63
Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation (2003) 1.63